Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects

被引:493
作者
Maruyama, Kazuo [1 ]
机构
[1] Teikyo Univ, Fac Pharmaceut Sci, Midori Ku, Sagamihara, Kanagawa 2525195, Japan
关键词
Liposome; PEG-liposome; Transferrin; Boron neutron-capture therapy (BNCT); Oxaliplatin; Passive targeting; Intracellular targeting; Fab' fragment; NEUTRON-CAPTURE THERAPY; PROLONGED CIRCULATION TIME; ANTITUMOR-ACTIVITY; MACROMOLECULAR THERAPEUTICS; COATED LIPOSOMES; FAB FRAGMENT; DOXORUBICIN; PHARMACOKINETICS; TRANSFERRIN; CANCER;
D O I
10.1016/j.addr.2010.09.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The success of an effective drug delivery system using liposomes for solid tumor targeting based on EPR effects is highly dependent on both size ranging from 100-200 nm in diameter and prolonged circulation half-life in the blood. A major development was the synthesis of PEG-liposomes with a prolonged circulation time in the blood. Active targeting of immunoliposomes to the solid tumor tissue can be achieved by the Fab' fragment which is better than whole IgG in terms of designing PEG-immunoliposomes with prolonged circulation. For intracellular targeting delivery to solid tumors based on EPR effects, transferrin-PEG-liposomes can stay in blood circulation for a long time and extravasate into the extravascular of tumor tissue by the EPR effect as PEG-liposomes. The extravasated transferrin-PEG-liposomes can maintain anti cancer drugs in interstitial space for a longer period, and deliver them into the cytoplasm of tumor cells via transferrin receptor-mediated endocytosis. Transferrin-PEG-liposomes improve the safety and efficacy of anti cancer drug by both passive targeting by prolonged circulation and active targeting by transferrin. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:161 / 169
页数:9
相关论文
共 59 条
[1]   Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol) [J].
Allen, C ;
Dos Santos, N ;
Gallagher, R ;
Chiu, GNC ;
Shu, Y ;
Li, WM ;
Johnstone, SA ;
Janoff, AS ;
Mayer, LD ;
Webb, MS ;
Bally, MB .
BIOSCIENCE REPORTS, 2002, 22 (02) :225-250
[2]   PHARMACOKINETICS OF STEALTH VERSUS CONVENTIONAL LIPOSOMES - EFFECT OF DOSE [J].
ALLEN, TM ;
HANSEN, C .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1068 (02) :133-141
[3]   Liposomal drug formulations - Rationale for development and what we can expect for the future [J].
Allen, TM .
DRUGS, 1998, 56 (05) :747-756
[4]   LIPOSOMES CONTAINING SYNTHETIC LIPID DERIVATIVES OF POLY(ETHYLENE GLYCOL) SHOW PROLONGED CIRCULATION HALF-LIVES INVIVO [J].
ALLEN, TM ;
HANSEN, C ;
MARTIN, F ;
REDEMANN, C ;
YAUYOUNG, A .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1066 (01) :29-36
[5]   IMMUNE CLEARANCE OF LIPOSOMES INHIBITED BY AN ANTI-FC RECEPTOR ANTIBODY INVIVO [J].
ARAGNOL, D ;
LESERMAN, LD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (08) :2699-2703
[6]  
BARTH RF, 1992, CANCER-AM CANCER SOC, V70, P2995
[7]  
BARTH RF, 1990, CANCER RES, V50, P1061
[8]   LIPOSOMES FOR THE SUSTAINED DRUG RELEASE INVIVO [J].
BLUME, G ;
CEVC, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1029 (01) :91-97
[9]   LIPOSOMAL DOXORUBICIN-INDUCED TOXICITY - DEPLETION AND IMPAIRMENT OF PHAGOCYTIC-ACTIVITY OF LIVER MACROPHAGES [J].
DAEMEN, T ;
HOFSTEDE, G ;
KATE, MTT ;
BAKKERWOUDENBERG, IAJM ;
SCHERPHOF, GL .
INTERNATIONAL JOURNAL OF CANCER, 1995, 61 (05) :716-721
[10]   UPTAKE AND PROCESSING OF IMMUNOGLOBULIN-COATED LIPOSOMES BY SUBPOPULATIONS OF RAT-LIVER MACROPHAGES [J].
DERKSEN, JTP ;
MORSELT, HWM ;
SCHERPHOF, GL .
BIOCHIMICA ET BIOPHYSICA ACTA, 1988, 971 (02) :127-136